10:44 AM EDT, 10/02/2024 (MT Newswires) -- TNF Pharmaceuticals ( TNFA ) said Wednesday that Prevail Partners has agreed to acquire 283,019 common shares of the company at $2.12 apiece.

TNF said it has engaged Prevail Partners affiliate Prevail InfoWorks to offer clinical services for the next phase 2 clinical study using TNF's sarcopenia drug candidate.

The company said it is now fully funded for clinical trials for the next two years.

TNF shares were up 3.9% in recent trading.

Price: 1.51, Change: +0.06, Percent Change: +3.93